Michael S. Perry
Known title: Chief Executive OfficerCIK: 0001250379
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
RCEL Gains Fair Value Lift After PermeaDerm Data and Q2 Beat. PermeaDerm data and a Q2 earnings beat lifted RCEL’s fair value. The news gave the stock a positive momentum boost. The lift comes as the company reports stronger‑than‑expected results and promising data from its PermeaDerm platform. The move is a short‑term reaction to the earnings beat and data release.
Transaction History
| ARWR | ▼ Sell | Open Market | 11,600 | $1.0M | 8/18/2026 | View on chart |
| ARWR | ▲ Buy | Grant | 7,819 | $0 | 12/16/2025 | View on chart |
| ARWR | ▼ Sell | Open Market | 16,250 | $992K | 12/5/2025 | View on chart |
| ARWR | ▲ Buy | Grant | 16,733 | $385K | 12/18/2024 | View on chart |
| ARWR | ▲ Buy | Grant | 14,987 | $381K | 12/15/2023 | View on chart |
| ARWR | ▲ Buy | Grant | 7,867 | $0 | 1/10/2023 | View on chart |
| RCEL | ▲ Buy | Option Exercise | 150,000 | $899K | 11/21/2022 | View on chart |
| RCEL | ▼ Sell | Open Market | 150,000 | $1.1M | 11/21/2022 | View on chart |
| RCEL | ▲ Buy | Grant | 2,980 | $0 | 9/1/2022 | View on chart |
| RCEL | ▼ Sell | Other | 23,754 | $0 | 6/1/2022 | View on chart |
| RCEL | ▼ Sell | Open Market | 10,812 | $94K | 2/24/2022 | View on chart |
| RCEL | ▲ Buy | Grant | 5,960 | $0 | 2/23/2022 | View on chart |
| RCEL | ▲ Buy | Grant | 23,753 | $0 | 2/23/2022 | View on chart |
| ARWR | ▲ Buy | Grant | 6,400 | $0 | 1/7/2022 | View on chart |
| ARWR | ▼ Sell | Open Market | 2,628 | $169K | 1/3/2022 | View on chart |
| ARWR | ▼ Sell | Open Market | 1,600 | $104K | 1/3/2022 | View on chart |
| ARWR | ▼ Sell | Open Market | 272 | $18K | 1/3/2022 | View on chart |
| RCEL | ▲ Buy | Grant | 23,820 | — | 12/22/2021 | View on chart |
| RCEL | ▲ Buy | Grant | 23,820 | — | 12/22/2021 | View on chart |
| RCEL | ▲ Buy | Grant | 23,800 | — | 12/22/2021 | View on chart |
| RCEL | ▼ Sell | Open Market | 11,220 | $232K | 9/1/2021 | View on chart |
| RCEL | ▲ Buy | Grant | 23,754 | $0 | 9/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Arrowhead to Share Alzheimer's Data; Analyst Notes Voucher Value
Arrowhead Pharmaceuticals announced it will host a webinar to present interim clinical data from a Phase 1/2a study of ARO-MAPT for Alzheimer’s disease. Separately, a Seeking Alpha article discussed the financial implications of a $215 million voucher, framing it within the context of fast-follower strategies. The stock is currently trading near its 52-week low, with an RSI of 29.8 indicating oversold conditions.
Arrowhead to Share Alzheimer's Data; Analyst Notes Voucher Value. Arrowhead Pharmaceuticals announced it will host a webinar to present interim clinical data from a Phase 1/2a study of ARO-MAPT for Alzheimer’s disease. Separately, a Seeking Alpha article discussed the financial implications of a $215 million voucher, framing it within the context of fast-follower strategies. The stock is currently trading near its 52-week low, with an RSI of 29.8 indicating oversold conditions.